Indication intelligence, analysis and sector perception

Global Blood Therapeutics (GBT) Prices a $150 M offering at $44.00 per share

December 7, 2018

GBT is down -$2.90% or -6.21% to $43.77

Regenerative Medicine Earnings Scorecard - Q3/18 - to date

November 23, 2018

Q3/18 financial results is a scorecard of  (AKA) earnings of 45 covered  companies 37 of 45 by 11/23   The current LPS (loss per share) or net income, cash positio, "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.  

Quarterly (Q3) results special: ADVM, HSGX, BTX, AGTC, ONVO, XON, BLFS, CLBS, PSTI, SGMO, STML and BSTG

November 9, 2018

Post reporting their Q’s; snapshots of LPS (loss-per-share) and net incomes - follow the bouncing share prices … A breakdown of reporting “figures” and commentary including Thursday’s closing numbers,: Adverum Biotechnologies (ADVM +$0.05), Histogenics (HSGX +$0.01), BioTime (NTSEMKT: BTX -$0.11), Applied Genetic Technologies (AGTC +$0.21), Intrexon (XON -$0.12), BioLife Solutions (BLFS +$0.16), Caladrius Bioscience (CLBS +$0.32), Pluristem (PSTI -$0.01), Sangamo Therapeutics (SGMO -$0.58), Stemline Therapeutics (STML -$0.36), Organovo Holdings (ONVO)  and Biostage (BSTG -$0.10)   Ben Graham used to talk about the stock market being a cross between a voting machine and a weighing machine   The market is still voting on Friday ...

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.